Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

By Dynavax Technologies

Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile

Newly presented data outline robust polyfunctional CD4+ T-cell responses in Z-1018 arms

Company initiates Part 2 of Phase 1/2 head-to-head versus Shingrix in adults 70 years and older